The importance of reporting patient recruitment details in phase III trials

Journal of Clinical Oncology

Volumn 24, Issue 6, 2006, Pages 843-845

  Wright, James R ^a   Bouma, Sarah ^b   Dayes, Ian ^a   Sussman, Jonathan ^a   Simunovic, Marko R ^a   Levine, Mark N ^a   Whelan, Tim J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; ESOPHAGUS CANCER; HUMAN; INFORMED CONSENT; MEDICAL LITERATURE; NOTE; PATIENT CARE; PATIENT PARTICIPATION; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; THERAPY EFFECT; TUMOR VOLUME; ARTICLE; METHODOLOGY; PHASE 3 CLINICAL TRIAL; STANDARD;

CLINICAL TRIALS, PHASE III; HUMANS; PATIENT SELECTION; RESEARCH DESIGN;

EID: 33644890187     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.6005     Document Type: Note

References (26)

1. Sackett D, Haynes B, Guyatt G, et al: Clinical Epidemiology: A Basic Science For Clinical Medicine (ed2). Boston, MA, Little Brown and Co, 1991
2. Grass P, Mallory R, Helat A, et al: Reporting the recruitment process in clinical trials: Who are these patients and how did they get there? Ann Intern Med 137:10-16, 2002
3. Pocock S: Clinical Trials: A Practical Approach. New York, NY, John Wiley & Sons, 1983, pp 35-38
4. Begg C, Cho M, Eastwood S, et al: Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA 276:637-639, 1996
5. Altman DG, Schulz K, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001
6. Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol 21:4592-4596, 2003
7. Malmstrom P, Homlberg L, Anderson H, et al: Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: A randomised clinical trial in a population with access to public mammography screening. Eur J Cancer 39:1690-1697, 2003
8. Smit EF, Jan P, van Meerbeeck P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment Of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909-3917, 2003
9. Moore MJ, Hamm J, Dancey J, et al: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor bay 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas - Phase III trial of the National Cancer Institute Of Canada Clinical Trials Group. J Clin Oncol 21:3296-3302, 2003
10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelionma. J Clin Oncol 21:2629-2630, 2003
11. Parnes HL, Cirrincione C, Aisner J, et al: Phase III study of cyclophosphamide, doxorubicin and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer And Leukemia Group B 9140. J Clin Oncol 21:1819-1824, 2003
12. Fuchs CS, Moore MR, Harker G: Phase III comparison of two irinotecan dosing regimens second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807-814, 2003
13. Bessell EM, Burton A, Haynes AP, et al: A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. Ann Oncol 14:258-267, 2003
14. Reck M, vanPawel J, Macha HN, et al: Radomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristin patients with small-cell lung cancer. J Natl Cancer Inst 95:1118-1127, 2003
15. Rovers MM, Zielhuis GA, Bennett K, et al: Generalisability of clinical trials in otitis media with effusion. Int J Pediatr Otorhinolaryngol 60:29-40, 2001
16. Begg CB, Engstrom P: Eligibility and extrapolation in cancer clinical trials. J Clin Oncol 5:962-968, 1987
17. Wright J, Fairclough L, Manzo J, et al: The metrics of clinical trials. J Clin Oncol 23:1589-1590, 2005
18. Hunter CP, Frelick RW, Feldman AR, et al: Selection factors in clinical trials: Results from the Community Clinical Oncology physician's patient log. Cancer Treat Rep 71:559-565, 1987
19. Klabunde CN, Springer BC, Butler B, et al: Factors influencing enrolment in clinical trials for cancer treatment. South Med J 92:1189-1193, 1999
20. Lara PN, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrolment. J Clin Oncol 19:1728-1733, 2001
21. Cassileth BR: Clinical trials: Time for action. J Clin Oncol 21:765-766, 2003
22. George S: Reducing patient eligibility criteria in cancer clinical trials. J Clin Oncol 14:1364-1370, 1996
23. Charlson ME, Horwitz RI: Applying results of randomised trials to clinical practice: Impact of losses before randomisation. BMJ (Clin Res Ed) 289:1281-1284, 1984
24. Moore DAJ, Goodall RL, Ives NJ, et al: How generalizable are the results of large randomized controlled trials of antiretroviral therapy? HIV Med 1:149-154, 2000
25. Bjorn M, Brendstrup C, Karlsen S, et al: Consecutive screening and enrolment in clinical trials: The way to representative patient samples? J Card Fail 4:225-230, 1998
26. Emanuel E, Schnipper L, Kamin D, et al: The non-treatment costs of conducting clinical research. J Clin Oncol 21:4145-4150, 2003